Navigation Links
VAP Test Demonstrates Value of Fish Oil in Reducing Heart Risk for Super Bowl Champs
Date:2/19/2009

g for treatment and lifestyle changes that can decrease the risk of a heart attack or stroke.

"We are now entering a new era of cardiac risk assessment," the study stated. "Newer specialized blood tests can fractionate blood lipids into many component molecules in order to better assess which lipid subfraction may possess a greater risk for causing disease."

The VAP Test, which is covered by most insurance providers and Medicare, provides physicians with direct measurement of LDL (bad cholesterol), HDL and all relevant cholesterol subclasses. These important but often overlooked subclasses include non-HDL, particle number as determined by accurate apoB, and emerging risk factors such as Lp(a), low-density lipoprotein remnants and small dense LDL.

Team Neurosurgeon for the Pittsburgh Steelers for the past 25 years and study co-author, Dr. Joseph Maroon, said the VAP Test identifies cardiovascular risks that a routine cholesterol test cannot. By using a subfraction cholesterol test (VAP test), therapeutic interventions can now be directed to specific and more potentially dangerous forms of cholesterol than the traditional total or "bad" cholesterols that have been targeted in the past, said Maroon, who also serves as vice chairman of neurological surgery at the University of Pittsburgh School of Medicine.

A number of factors can put athletes at increased risk of high blood pressure, high cholesterol and obesity, which may also lead to metabolic syndrome, a precursor to diabetes--all which point to heart disease.

"The professional football player statistically is at increased risk for future cardiovascular disease and sudden heart attack," Atherotech's Chief Medical Officer Dr. James Ehrlich said. "This study thoroughly demonstrates that fish oil improved good cholesterol and lowered damaging particles and triglycerides."

The VAP Test is also the only comm
'/>"/>

SOURCE Atherotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
2. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
3. Sparta Systems Demonstrates Global Enterprise Quality Management Leadership at TrackWise(R) Connection User Conferences
4. Human clinical study demonstrates superior Neptune Krill Oil NKO(R) pharmacokinetic profile
5. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
6. RVX-208 Data Demonstrates Increase in Functional HDL Particles
7. Study From the University of Texas M.D. Anderson Cancer Center Demonstrates That AHCC(R) is Safe in Combination With Most Chemotherapeutic Agents
8. Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
9. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
10. SuperGens MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
11. SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... WriteResult, LLC – a premier ... working with a team of researchers from Yale University’s ... Farming Collaborative to provide electronic questionnaire data collection through ... which started in May, aims to evaluate the impact ... exposure to and participation in urban agriculture to impact ...
(Date:10/22/2014)... Oct. 22, 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, announced today that ... Notice of Allowance for a composition of matter patent ... difficile program, SYN-004. This is Synthetic Biologics, first ... U.S. and adds to the Company,s extensive C. ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market by ... Systems, Table-top Counters) by End-user (Inpatient Pharmacy Automation, ... to 2019” analyzes and studies the major market ... Asia-Pacific, and the Rest of the World (RoW). ... spread through 300 pages and in-depth TOC on ...
(Date:10/20/2014)... 2014 , A major pan-European ... the delivery of care has revealed changing trends in ... in the provision of healthcare services across the continent. ... United European Gastroenterology (UEG), have been announced today and ... of the burden of GI disorders across ...
Breaking Biology Technology:myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5
... matrix for dry state room temperature transport and ... ... GenVault Corporation, the,leader in dry, room temperature biosample management, ... DNA is a,proprietary inorganic matrix with built-in oxidative protection and,antimicrobial ...
... Pharmasset, Inc.,(Nasdaq: VRUS ) management will present ... from October 13-14, 2008 at the Waldorf Astoria,in ... Officer, will,provide an overview of the company on ... About Pharmasset, Pharmasset is a clinical-stage pharmaceutical ...
... Colo., Oct. 8 GeneThera, Inc.,(Pink Sheets: GTHR), ... Chairman and CEO, Dr. Tony Milici, is featured ... The interview gives viewers an overview of ... press release., To view the clip ...
Cached Biology Technology:GenVault Corporation Launches GenTegra(TM) DNA 2GenVault Corporation Launches GenTegra(TM) DNA 3[video] Dr. Tony Milici, Chairman and CEO of GeneThera, Inc., Discusses Worldwide Rights to E.Coli Vaccine on WallSt.net's 3-Minute Press Show 2
(Date:10/22/2014)... 2014 Aware, Inc. (NASDAQ: AWRE ), ... financial results for its third quarter ended September 30, 2014. ... $6.0 million, an increase of 40% compared to $4.3 million ... third quarter of 2014 was $4.1 million compared to $1.0 ... in the current three month period was primarily due to: ...
(Date:10/18/2014)... undiagnosed, suspected genetic conditions, a certain type of exome ... yield than traditional molecular diagnostic methods, according to a ... being released to coincide with the American Society of ... the protein­coding region of the genome (the complete set ... or organism), has been rapidly applied in research settings ...
(Date:10/17/2014)... news release is available in German . ... only a very few drugs. When treating overdoses, doctors are ... is especially difficult if there is a combination of drugs ... playing and accidentally swallows his grandmother,s pills? ETH professor Jean-Christophe ... wanted to find an answer to this question. "The task ...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Emergency aid for overdoses 2Emergency aid for overdoses 3
... with the most commonly performed weight-loss surgery appears to ... but serious complication, according to a study published in ... Robotic Surgery. Minimally-invasive surgeons at The University ... times, length of hospital stay and complications in 605 ...
... Health Science Center at Houston plans to scan the genomes ... why blood pressure often increases as young adults age. ... funded with a new $1.1 million grant from the Genes, ... Health. The grant was one of six announced today during ...
... treatment for depression could soon be only a ... National Space Biomedical Research Institute (NSBRI) are developing ... in recognizing and effectively managing depression and other ... to crew safety and mission operations during long-duration ...
Cached Biology News:Robotic surgery lowers risk of a rare but serious complication of gastric bypass 2Scientist plans to test for blood pressure genes affected by age 2Coming soon: Self-guided, computer-based depression treatment 2Coming soon: Self-guided, computer-based depression treatment 3
... Intracellular (IC) Fixation Buffer, used in ... No. 00-8333), can be used to ... performing intracellular staining of cytokines and ... solutions have been specially formulated for ...
... Perm Buffer III ... following fixation of PBMCs ... for staining for intracellular ... markers simultaneously. Applications: ...
Permeabilization Solution, 5X...
Perm/Wash Buffer 250 Tests...
Biology Products: